OBJECTIVE: This study compared a-blocker monotherapy with combination therapy involving an a-blocker and a 5-a reductase inhibitor for benign prostatic hyperplasia (BPH), according to baseline prostate volume. METHODS: Korean men diagnosed with BPH were randomized to 12 months' treatment with 0.2 mg tamsulosin or 0.2 mg tamsulosin plus 0.5 mg dutasteride. Prostate specific antigen (PSA), prostate volume, transition zone volume (TZV), International Prostate Symptom Score (IPSS), maximal urinary flow rate (Q max ), postvoid residual urine volume and sexual function were assessed at baseline and after 12 months' treatment. Variables were analysed based on baseline prostate volumes of ≤ 35 ml or > 35 ml. RESULTS: In total, 216 men with BPH were included. Combination therapy resulted in significant improvements in prostate volume, TZV, PSA, IPSS and Q max , which were most pronounced in men with a prostate volume > 35 ml. CONCLUSIONS: Tamsulosin monotherapy was sufficient treatment for BPH in Korean men with a prostate volume ≤ 35 ml. Combination tamsulosin and dutasteride therapy provided greater benefits than tamsulosin monotherapy in men with BPH whose prostate volume was > 35 ml.
Introduction
Benign prostatic hyperplasia (BPH) is a progressive disease that causes lower urinary tract symptoms (LUTS) which substantially affect quality of life for many patients. 1 Progression of BPH results in more severe LUTS, as well as other symptoms and episodes such as reduction of urinary flow rate, increased incidence of urinary infection, acute urinary retention and increased incidence of surgery for BPH. 1, 2 The α-adrenergic blockers (α-blockers) and 5α-reductase inhibitors (5-ARIs) are commonly used to treat patients with BPH. Prostatic smooth muscle plays a key role in the development of prostatic urethral pressure, which results in LUTS in patients with BPH. Since there are many α-adrenergic receptors within the prostatic smooth muscle, blocking the α-adrenergic receptor signal relieves the symptoms of BPH. The use of 5-ARIs reduces prostate volume by 20 -30%, thereby relieving obstructive symptoms in BPH patients. 3,4 α-Blocker monotherapy is commonly used to treat BPH patients who have a small prostate volume, whereas α-blocker/5-ARI combination therapy is commonly used to treat BPH patients who have a large prostate volume. The Medical Therapy of Prostatic Symptoms (MTOPS) study indicated that combination therapy was beneficial when the prostate volume was > 40 ml and the serum prostate specific antigen (PSA) concentration was > 4.0 ng/ml. 5 It is unknown whether these standards also apply to the Korean population. The CombAT study suggested that combination therapy with 0.4 mg tamsolusin and 0.5 mg dutasteride was effective in patients with a prostate volume > 30 ml. 6 Unlike Western countries, where 0.4 mg tamsulosin once daily therapy is used, in Asian countries such as the Republic of Korea, China, Japan, Taiwan and Singapore, 0.2 mg tamsulosin once daily is the recommended dosage for treating BPH.
The present study compared the efficacy and safety of monotherapy (0.2 mg tamsulosin, once daily) with combination therapy (0.2 mg tamsulosin/0.5 mg dutasteride, once daily), according to baseline prostate volume, in Korean men with BPH. K-J Joo, W-S Sung, S-H Park et al. a-Blocker and 5a-reductase inhibitor treatment for BPH blocker/5-ARI combination therapy (0.2 mg tamsulosin, orally, once daily plus 0.5 mg dutasteride, orally, once daily; Group 2) for 12 months. Patients were asked to attend follow-up appointments at their treatment centres every 3 months.
Prostate volume, transition zone volume (TZV), uroflowmetry and residual urine volume were measured before and after 12 months' treatment. In addition, participants were asked to complete the following questionnaires: the IPSS, with symptoms classified as mild (scores 0 -7), moderate (scores 8 -19), or severe (scores 20 -35); 9 the International Index of Erectile Function (IIEF), which classifies the severity of erectile dysfunction into five categories (severe [scores 5 -7], moderate [scores 8 -11], mild to moderate [scores 12 -16] , mild [scores 17 -21] , and no erectile dysfunction [scores 22 -25]); 10 and the Male Sexual Health Questionnaire (MSHQ: 11 out of the 25 items, only the seven items for ejaculation were assessed in the present study). Each questionnaire was completed before and after 12 months' treatment and scores were compared to determine whether there were any significant changes over time. Treatment effects of mono-and combination therapy on prostate volume were compared in patients, divided into those with a baseline prostate volume ≤ 35 ml and those with a baseline volume > 35 ml. The primary endpoint was the change in IPSS or Q max from baseline for monotherapy versus combination therapy in patients with a baseline prostate volume ≤ 35 ml or > 35 ml. Adverse events were assessed by the investigator at every 3-month follow-up visit.
STATISTICAL ANALYSES
Statistical analyses were carried out using SPSS ® statistical software, version 15.0 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Differences between the two treatment groups were compared using Student's t-test and the incidence of adverse events was analysed using Pearson's χ 2 -test. A P-value < 0.05 was considered to be statistically significant.
Results
In total, 216 participants met the inclusion criteria and were enrolled. Of these, 23 (10.6%) were unable to complete the study: eight (3.7%) dropped out due to a desire to stop treatment; five (2.3%) were excluded due to modification of the treatment plan to surgical intervention; five (2.3%) dropped out due to adverse events such as impotence and retrograde ejaculation; four (1.9%) dropped out due to orthostatic hypotension; one (0.5%) dropped out due to dyspepsia. A total of 95 patients in Group 1 and 98 patients in Group 2 completed the trial. Baseline parameters are shown in Table 1 . There were no significant between-group differences in terms of baseline parameters.
After 12 months' treatment, patients in Group 1 showed a significant reduction in IPSS and residual urine volume, and a significant increase in Q max (Table 1 ; P < 0.05, all comparisons). In Group 2, a significant reduction in PSA concentration, prostate volume, TZV, IPSS and residual urine volume, and a significant increase in Q max , were observed (Table 1 ; P < 0.05, all comparisons). IIEF and MSHQ scores did not change significantly in either group across the study period (Table 1) .
In total, 52 patients from Group 1 and 51 patients from Group 2 had a baseline prostate volume ≤ 35 ml, whereas 43 patients from Group 1 and 47 patients from Group 2 had a baseline prostate volume > 35 ml. At baseline there were no significant differences between Groups 1 and 2, stratified by prostate volume (Tables 2 and 3 ). a-Blocker and 5a-reductase inhibitor treatment for BPH MSHQ, Male Sexual Health Questionnaire. 11 a-Blocker and 5a-reductase inhibitor treatment for BPH After 12 months' treatment in patients with a baseline prostate volume ≤ 35 ml, prostate volume increased by 2.4% in Group 1 but decreased by 20.6% in Group 2, TZV increased by 2.0% in Group 1 but decreased by 17.0% in Group 2, and PSA concentration decreased by 2.4% in Group 1 and by 38.5% in Group 2 (Table 2) . There was a significant between-group difference in the change from baseline at 12 months for all three parameters ( Table 2 ; P < 0.05).
After 12 months' treatment in patients with a baseline prostate volume > 35 ml, prostate volume increased by 1.6% in Group 1 but decreased by 31.0% in Group 2, TZV increased by 1.4% in Group 1 but decreased by 21.3% in Group 2, PSA concentration decreased by 4.0% and by 42.6% in Groups 1 and 2, respectively, and Q max increased by 22.4% and by 41.5% in Groups 1 and 2, respectively (Table 3) . There was a significant between-group difference in the change from baseline at 12 months for all four parameters (Table 3 ; P < 0.05). There were no significant between-group differences for the remaining variables after 12 months in men with a baseline prostate volume of ≤ 35 ml or > 35 ml (Tables 2 and 3 ).
The incidence of adverse events recorded during the study is reported in Table 4; there were no significant between-group differences.
Discussion
The clinical effects of α-blockers in relieving obstructive symptoms in patients with BPH, by relaxing prostatic smooth muscles, are well defined. 7,12 Tamsulosin, a selective α 1aadrenergic receptor blocker, is a commonly used treatment for BPH and has proven efficacy and a good safety profile. 8, 13 -15 The 5-ARIs block the action of the 5α-reductase enzymes that convert testosterone into dihydrotestosterone (DHT, which normally promotes prostate growth) and reduce prostate size to relieve obstructive symptoms. 3 Dutasteride inhibits both isoforms of 5α-reductase (types I and II), and has a 45-fold greater affinity for type I and a 2.5-fold greater affinity for type II than finasteride. As a result of this higher affinity, dutasteride effectively inhibits DHT much more rapidly than finasteride. 16 The management of BPH focuses not only on reduction of LUTS, but also on prevention of BPH progression. Several studies have demonstrated that the use of 5-ARIs reduces adverse events in the progression of BPH. 3, 5, 7 The PREDICT study and the Veterans Affairs Cooperative Study reported that 12 months' Data presented as n (%) of patients. There were no statistically significant difference between groups (P ≥ 0.05 for all comparisons); Pearson's χ 2 -test. Group 1, monotherapy with 0.2 mg tamsulosin, orally once daily; Group 2, combination therapy with 0.2 mg tamsulosin, orally once daily plus 0.5 mg dutasteride, orally once daily. a-Blocker and 5a-reductase inhibitor treatment for BPH combination therapy with an α-blocker plus a 5-ARI was no more beneficial than αblocker monotherapy in terms of symptom relief and urine flow rate. 7, 17 The 4-year PLESS study, however, 18 reported that finasteride therapy reduced the need for surgical treatment by 50%. Moreover, according to the MTOPS study (which lasted for 4.5 years), the risk of acute urinary retention was lower in groups treated with finasteride or with the combination of an αblocker and 5-ARI, compared with groups treated with doxazosin. 5 The MTOPS study also reported that α-blocker monotherapy only delayed BPH-associated adverse events (such as acute urinary retention), whereas combination therapy with an α-blocker and a 5-ARI reduced both the risk of adverse events and the need for surgical intervention. 5 Combination therapy with an α-blocker and a 5-ARI is theoretically ideal because αblockers treat biokinetic factors associated with prostatic smooth muscle and 5-ARIs treat anatomical factors associated with BPH. The optimal combination has, however, yet to be determined. In patients from the Republic of Korea, it has been reported that there are no significant differences between combination therapy and monotherapy in terms of treatment effects for a prostate volume < 40 ml. 19 The MTOPS study reported that combination therapy was effective in patients with a prostate volume ≥ 40 ml. 5 Even though the frequency of LUTS in the Korean population is the same as that in Western populations, prostate volume and PSA concentrations are lower in the Korean population. Multicentre research in Korean patients indicates that the 40-ml standard for a large prostate in Western populations can be translated to 35 ml in the local Korean population. 20 Thus, the present study used 35 ml as the standard prostate volume to differentiate large and small prostates when comparing the treatment effects of monotherapy and combination therapy. In patients with a baseline prostate volume ≤ 35 ml, prostate volume, TZV and PSA concentrations were significantly reduced after 12 months' combination therapy compared with monotherapy. Symptoms were relieved in both groups and changes in the IPSS, Q max , residual urine volume and other variables were not significantly different. In patients with a baseline prostate volume > 35 ml, decreases in prostate volume, TZV and PSA concentrations after combination therapy were greater than those observed in the group with a baseline prostate volume ≤ 35 ml. Thus, the reductions in PSA and prostate volume were greater in patients with an initially larger prostate volume. In addition, Q max was significantly increased in the combination therapy group compared with the monotherapy group with a baseline prostate volume > 35 ml.
Most of the adverse events reported in the present study were related to sexual function and were more frequently observed in the combination therapy group, although such symptoms were minimal and were not significantly different between the two groups. The frequency of retrograde ejaculation (which is a known side-effect of α 1a -selective blockers) was the same in both groups. Adverse events observed with 5-ARIs (such as erectile dysfunction and decreased libido) were more frequently reported in patients receiving combination therapy, although the difference was not significantly different between the two groups. In addition, there were no significant betweengroup differences in the IIEF and MSHQ scores. It could be inferred that psychological factors play a role in the development of • Received for publication 23 January 2012 • Accepted subject to revision 5 February 2012
• Revised accepted 13 April 2012 Copyright © 2012 Field House Publishing LLP side-effects, but that these events are not substantial enough to affect daily life.
In conclusion, in the population of Korean men that was studied, α-blocker monotherapy was a suitable treatment for BPH patients with a prostate volume ≤ 35 ml. In Korean BPH patients with a prostate volume > 35 ml, α-blocker plus 5-ARI combination therapy was more beneficial than α-blocker monotherapy.
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